BioCentury | Oct 2, 2020

From Termeer to scuttled Allergan deal, Lysosomal’s winding road continues with Bial takeout

A takeout by Bial brings to an end Lysosomal’s search for a partner to advance its Parkinson’s programs after Allergan turned down its option to acquire the biotech last year.  Portugal-based Bial...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Sep 7, 2020
Product Development

Covert disease surveillance capacity needed to detect future pandemics, says Gottlieb: a BioCentury audio interview

The U.S. must treat the threat of future pandemics as a national security issue, former FDA Commissioner Scott Gottlieb told BioCentury. In a Back to School audio interview, Gottlieb called for intensified pandemic planning, government...
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head of enterprise partnership. His appointment comes as BIO rolls out its BIOEquality...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Jun 23, 2020
Politics, Policy & Law

As deadline approaches, Senate introduces voucher program renewal bill

With three months left until Congress’ deadline to reauthorize the rare pediatric disease Priority Review voucher program, two senators introduced legislation late last week to make the program permanent. FDA awards a voucher upon the...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

This story was updated to reflect additional comments from FDA that were provided after publication of the initial version. Cronyism has crippled America’s pandemic response, enriching undeserving entrepreneurs and politically potent consultants who siphoned funds...
BioCentury | Apr 2, 2020

Billion-dollar funds from Arch, Flagship show VCs are open for business

Two of biotech’s most prominent company builders, Arch Venture Partners and Flagship Pioneering, unveiled new funds that raised nearly $2.6 billion in total, showing the sector can attract substantial capital even in the midst of...
Items per page:
1 - 10 of 340